This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sato, T. Articles by Nakamura, Y. Search for Related Content PubMed PubMed Citation Articles by Sato, T. Articles by Nakamura, Y.

Allelotype of Human Ovarian Cancer¹

Departments of Biochemistry [T. S., H. S., R. M., Y. N.] and Gynecology [S. K.], Cancer Institute, Tokyo, 1-37-1, Kami-Ikebukuro, Toshima-ku, Tokyo 170, Japan, and Department of Biochemistry, Korea Cancer Institute Hospital [J-H. L.], Seoul, Korea

In order to determine which chromosome(s) carries a tumor suppressor gene(s) for human ovarian cancer, we examined loss of heterozygosity in 37 tumors with a set of polymorphic DNA markers which cover each autosomal chromosome arm partially.

Frequent losses were observed in chromosomes 4p (42%), 6p (50%), 7p (43%), 8q (31%), 12p (38%), 12q (33%), 16p (33%), 16q (38%), 17p (46%), 17q (39%), and 19p (34%). In addition to these chromosomes, frequent losses of alleles on chromosomes 6q, 13q, and 19q were observed uniquely in serous and serous papillary cystadenocarcinomas; loss of heterozygosity was detected only rarely on these chromosomal arms in nonserous types of tumors. The average (0.12) of fractional allelic loss seen in mucinous cystadenocarcinoma, which usually has a better prognosis than other types, was much lower than that of other tumor phenotypes including serous cystadenocarcinoma (0.31) and clear cell carcinoma (0.20).

These results suggested that (a) a large number of tumor suppressor genes might play a role in ovarian cancer, (b) losses of alleles in different chromosomal regions could account for differences in histopathological features and/or prognoses among patients, and (c) this kind of analysis can contribute to an improved understanding of tumor development and/or progression in human ovarian cancer.

¹ The work was partly supported by a Grant-in-Aid for Cancer Research from the Ministry of Education, Science and Culture of Japan, and the Ministry of Science and Technology of Korea.

² To whom requests for reprints should be addressed, at Department of Biochemistry, Cancer Institute, Tokyo, 1-37-1, Kami-Ikebukuro, Toshima-ku, Tokyo 170, Japan.

Received 4/15/91. Accepted 7/15/91.

This article has been cited by other articles:

				S. Ulisse, E. Baldini, M. Toller, J.-G. Delcros, A. Gueho, F. Curcio, E. De Antoni, L. Giacomelli, F. S Ambesi-Impiombato, S. Bocchini, et al. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues Endocr. Relat. Cancer, September 1, 2007; 14(3): 827 - 837. [Abstract] [Full Text] [PDF]

				C. M. Feltmate, K. R. Lee, M. Johnson, J. O. Schorge, K.-k. Wong, K. Hao, W. R. Welch, D. A. Bell, R. S. Berkowitz, and S. C. Mok Whole-Genome Allelotyping Identified Distinct Loss-of-Heterozygosity Patterns in Mucinous Ovarian and Appendiceal Carcinomas Clin. Cancer Res., November 1, 2005; 11(21): 7651 - 7657. [Abstract] [Full Text] [PDF]

				P. B. Makarla, M. H. Saboorian, R. Ashfaq, K. O. Toyooka, S. Toyooka, J. D. Minna, A. F. Gazdar, and J. O. Schorge Promoter Hypermethylation Profile of Ovarian Epithelial Neoplasms Clin. Cancer Res., August 1, 2005; 11(15): 5365 - 5369. [Abstract] [Full Text] [PDF]

				Y. Takahashi, Y. Miyoshi, C. Takahata, N. Irahara, T. Taguchi, Y. Tamaki, and S. Noguchi Down-Regulation of LATS1 and LATS2 mRNA Expression by Promoter Hypermethylation and Its Association with Biologically Aggressive Phenotype in Human Breast Cancers Clin. Cancer Res., February 15, 2005; 11(4): 1380 - 1385. [Abstract] [Full Text] [PDF]

				K. Holcomb, R. Delatorre, B. Pedemonte, C. McLeod, L. Anderson, and J. Chambers E-Cadherin Expression in Endometrioid, Papillary Serous, and Clear Cell Carcinoma of the Endometrium Obstet. Gynecol., December 1, 2002; 100(6): 1290 - 1295. [Abstract] [Full Text] [PDF]

				A. Rathi, A. K. Virmani, J. O. Schorge, K. J. Elias, R. Maruyama, J. D. Minna, S. C. Mok, L. Girard, D. A. Fishman, and A. F. Gazdar Methylation Profiles of Sporadic Ovarian Tumors and nonmalignant Ovaries from High-Risk Women Clin. Cancer Res., November 1, 2002; 8(11): 3324 - 3331. [Abstract] [Full Text] [PDF]

				A J Alvi, R Hogg, J S Rader, M J Kuo, E R Maher, and F Latif Mutation screening analysis of the retinoblastoma related gene RB2/p130 in sporadic ovarian cancer and head and neck squamous cell cancer Mol. Pathol., June 1, 2002; 55(3): 153 - 155. [Abstract] [Full Text] [PDF]

				I. Tomlinson, P. Sasieni, and W. Bodmer How Many Mutations in a Cancer? Am. J. Pathol., March 1, 2002; 160(3): 755 - 758. [Full Text] [PDF]

				H. Lassus, R. Salovaara, L. A. Aaltonen, and R. Butzow Allelic Analysis of Serous Ovarian Carcinoma Reveals Two Putative Tumor Suppressor Loci at 18q22-q23 Distal to SMAD4, SMAD2, and DCC Am. J. Pathol., July 1, 2001; 159(1): 35 - 42. [Abstract] [Full Text] [PDF]

				K. Kurose, X.-P. Zhou, T. Araki, S. A. Cannistra, E. R. Maher, and C. Eng Frequent Loss of PTEN Expression Is Linked to Elevated Phosphorylated Akt Levels, but Not Associated with p27 and Cyclin D1 Expression, in Primary Epithelial Ovarian Carcinomas Am. J. Pathol., June 1, 2001; 158(6): 2097 - 2106. [Abstract] [Full Text] [PDF]

				V. W. Wang, D. A. Bell, R. S. Berkowitz, and S. C. Mok Whole Genome Amplification and High-Throughput Allelotyping Identified Five Distinct Deletion Regions on Chromosomes 5 and 6 in Microdissected Early-Stage Ovarian Tumors Cancer Res., May 1, 2001; 61(10): 4169 - 4174. [Abstract] [Full Text]

				R. L. Baldwin, E. Nemeth, H. Tran, H. Shvartsman, I. Cass, S. Narod, and B. Y. Karlan BRCA1 Promoter Region Hypermethylation in Ovarian Carcinoma: A Population-based Study Cancer Res., October 1, 2000; 60(19): 5329 - 5333. [Abstract] [Full Text]

				Y. Harima, K. Harima, S. Sawada, Y. Tanaka, S. Arita, and T. Ohnishi Loss of Heterozygosity on Chromosome 6p21.2 as a Potential Marker for Recurrence after Radiotherapy of Human Cervical Cancer Clin. Cancer Res., March 1, 2000; 6(3): 1079 - 1085. [Abstract] [Full Text]

				P. Fullwood, S. Marchini, J. S. Rader, A. Martinez, D. Macartney, M. Broggini, C. Morelli, G. Barbanti-Brodano, E. R. Maher, and F. Latif Detailed Genetic and Physical Mapping of Tumor Suppressor Loci on Chromosome 3p in Ovarian Cancer Cancer Res., September 1, 1999; 59(18): 4662 - 4667. [Abstract] [Full Text] [PDF]

				A. S. Yustein, J. C. Harper, G. R. Petroni, O. W. Cummings, C. A. Moskaluk, and S. M. Powell Allelotype of Gastric Adenocarcinoma Cancer Res., April 1, 1999; 59(7): 1437 - 1441. [Abstract] [Full Text] [PDF]

				H. Lin, R. Huber, D. Schlessinger, and P. J. Morin Frequent Silencing of the GPC3 Gene in Ovarian Cancer Cell Lines Cancer Res., February 1, 1999; 59(4): 807 - 810. [Abstract] [Full Text] [PDF]

				K. Helin, K. Holm, A. Niebuhr, H. Eiberg, N. Tommerup, S. Hougaard, H. S. Poulsen, M. Spang-Thomsen, and P. Norgaard Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma PNAS, June 24, 1997; 94(13): 6933 - 6938. [Abstract] [Full Text] [PDF]

				E Solomon, J Borrow, and A. Goddard Chromosome aberrations and cancer Science, November 22, 1991; 254(5035): 1153 - 1160. [Abstract] [PDF]